Reduction in hives

74^%	reduction in hives with Xolair^® 300 mg vs baseline at 12 weeks*^1,2

44^%	of patients were itch- and hive-free with Xolair^® 300 mg at 12 weeks*¹

66^%	of patients were well-controlled with Xolair^® 300 mg vs baseline at 12 weeks*^‡1

Simple dosing schedule

Xolair^® is administered by
subcutaneous injection, using a pre-filled syringe^‡3

Find out more

Well tolerated

Xolair^® was well tolerated
in over 700 patients
in the CSU phase III
clinical program³

Find out more

Model is a hypothetical patient profile, for illustrative purposes only

*Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients

**Xolair® is also available as a lyophilized formulation

^†Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs placebo.

^‡A patient with a UAS7 score of 1-6 will have well-controlled CSU over 7 days⁴

References: 1. Maurer M, et al. N Engl J Med 2013;368:924-935. 2. Bernstein JA, et al. J Allergy Clin Immunol 2014;133(Suppl 2):AB117 (poster). 3. Xolair® Summary of Product Characteristics 2016.

NP4 code: GLDEIM/IGE025E/0181